Based on results of the phase III NETTER-1 trial, lutathera (lutetium [177Lu] oxodotreotide) has been approved by the FDA for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). {read more here}